company background image
NBIX

Neurocrine BiosciencesNasdaqGS:NBIX Stock Report

Market Cap

US$8.0b

7D

-1.5%

1Y

-10.7%

Updated

30 Nov, 2021

Data

Company Financials +
NBIX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance6/6
Financial Health5/6
Dividends0/6

NBIX Stock Overview

Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders.

Neurocrine Biosciences Competitors

Teva Pharmaceutical Industries

NYSE:TEVA

US$9.4b

Price History & Performance

Summary of all time highs, changes and price drops for Neurocrine Biosciences
Historical stock prices
Current Share PriceUS$84.74
52 Week HighUS$120.27
52 Week LowUS$84.50
Beta0.70
1 Month Change-19.61%
3 Month Change-10.99%
1 Year Change-10.74%
3 Year Change-5.87%
5 Year Change94.31%
Change since IPO577.92%

Recent News & Updates

Nov 08

Neurocrine Biosciences: Generic Drug Stock Seen As Underpriced By Market-Makers For Near Gains

Sharp down days are when to look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media - everyone knows them. The hidden values are ones found by experienced professional researchers who know the details of industry group issues and their special strengths. They know when to add them to their institutional employer’s multi-billion-$ portfolio. That’s when sudden forced Market-Maker liquidity requires price protection by hedging. For investor portfolios where wealth-building is a principal objective, this is the place to find near-term capital gain reliability.

Oct 02
I Ran A Stock Scan For Earnings Growth And Neurocrine Biosciences (NASDAQ:NBIX) Passed With Ease

I Ran A Stock Scan For Earnings Growth And Neurocrine Biosciences (NASDAQ:NBIX) Passed With Ease

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Aug 27
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

NBIXUS BiotechsUS Market
7D-1.5%2.0%-0.9%
1Y-10.7%4.9%23.3%

Return vs Industry: NBIX underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: NBIX underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is NBIX's price volatile compared to industry and market?
NBIX volatility
NBIX Average Weekly Movement4.3%
Biotechs Industry Average Movement8.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: NBIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: NBIX's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992917Kevin Gormanhttps://www.neurocrine.com

Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia.

Neurocrine Biosciences Fundamentals Summary

How do Neurocrine Biosciences's earnings and revenue compare to its market cap?
NBIX fundamental statistics
Market CapUS$8.04b
Earnings (TTM)US$444.80m
Revenue (TTM)US$1.07b

18.1x

P/E Ratio

7.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NBIX income statement (TTM)
RevenueUS$1.07b
Cost of RevenueUS$320.50m
Gross ProfitUS$748.90m
ExpensesUS$304.10m
EarningsUS$444.80m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)4.69
Gross Margin70.03%
Net Profit Margin41.59%
Debt/Equity Ratio24.6%

How did NBIX perform over the long term?

See historical performance and comparison

Valuation

Is Neurocrine Biosciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NBIX ($84.74) is trading below our estimate of fair value ($288.09)

Significantly Below Fair Value: NBIX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NBIX is good value based on its PE Ratio (18.1x) compared to the US Biotechs industry average (25x).

PE vs Market: NBIX is poor value based on its PE Ratio (18.1x) compared to the US market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: NBIX is good value based on its PEG Ratio (0.5x)


Price to Book Ratio

PB vs Industry: NBIX is overvalued based on its PB Ratio (6x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Neurocrine Biosciences forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?

34.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NBIX's forecast earnings growth (34.8% per year) is above the savings rate (2%).

Earnings vs Market: NBIX's earnings (34.8% per year) are forecast to grow faster than the US market (14.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NBIX's revenue (17.7% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: NBIX's revenue (17.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NBIX's Return on Equity is forecast to be high in 3 years time (22.3%)


Past Performance

How has Neurocrine Biosciences performed over the past 5 years?

77.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NBIX has high quality earnings.

Growing Profit Margin: NBIX's current net profit margins (41.6%) are higher than last year (9%).


Past Earnings Growth Analysis

Earnings Trend: NBIX has become profitable over the past 5 years, growing earnings by 77.6% per year.

Accelerating Growth: NBIX's earnings growth over the past year (376.2%) exceeds its 5-year average (77.6% per year).

Earnings vs Industry: NBIX earnings growth over the past year (376.2%) exceeded the Biotechs industry 11%.


Return on Equity

High ROE: NBIX's Return on Equity (33%) is considered high.


Financial Health

How is Neurocrine Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: NBIX's short term assets ($1.0B) exceed its short term liabilities ($225.9M).

Long Term Liabilities: NBIX's short term assets ($1.0B) exceed its long term liabilities ($445.4M).


Debt to Equity History and Analysis

Debt Level: NBIX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if NBIX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: NBIX's debt is well covered by operating cash flow (104.9%).

Interest Coverage: NBIX's interest payments on its debt are well covered by EBIT (9.7x coverage).


Balance Sheet


Dividend

What is Neurocrine Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NBIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NBIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NBIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NBIX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NBIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Kevin Gorman (63 yo)

13.83yrs

Tenure

US$13,880,632

Compensation

Dr. Kevin C. Gorman, Ph D., has been the President and Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008. Dr. Gorman is a Founder of Neurocrine Biosciences, Inc. Dr. Gorman was Exe...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD13.88M) is above average for companies of similar size in the US market ($USD6.23M).

Compensation vs Earnings: Kevin's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: NBIX's management team is seasoned and experienced (6.8 years average tenure).


Board Members

Experienced Board: NBIX's board of directors are seasoned and experienced ( 10.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Neurocrine Biosciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Neurocrine Biosciences, Inc.
  • Ticker: NBIX
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$8.039b
  • Shares outstanding: 94.87m
  • Website: https://www.neurocrine.com

Number of Employees


Location

  • Neurocrine Biosciences, Inc.
  • 12780 El Camino Real
  • San Diego
  • California
  • 92130
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 00:10
End of Day Share Price2021/11/29 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.